Neuberger Berman Group LLC Buys 635,676 Shares of Emergent Biosolutions Inc (NYSE:EBS)

Neuberger Berman Group LLC increased its holdings in Emergent Biosolutions Inc (NYSE:EBS) by 27.0% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,988,473 shares of the biopharmaceutical company’s stock after acquiring an additional 635,676 shares during the period. Neuberger Berman Group LLC owned about 5.65% of Emergent Biosolutions worth $236,120,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. Rockefeller Capital Management L.P. lifted its stake in Emergent Biosolutions by 112.7% in the first quarter. Rockefeller Capital Management L.P. now owns 453 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 240 shares during the last quarter. Assetmark Inc. purchased a new stake in shares of Emergent Biosolutions in the second quarter worth $33,000. FDx Advisors Inc. bought a new position in Emergent Biosolutions in the first quarter valued at $37,000. First Mercantile Trust Co. bought a new position in Emergent Biosolutions in the second quarter valued at $73,000. Finally, Creative Financial Designs Inc. ADV bought a new position in Emergent Biosolutions in the second quarter valued at $89,000.

A number of brokerages have recently issued reports on EBS. Cantor Fitzgerald raised their price objective on Emergent Biosolutions from $85.00 to $110.00 and gave the company an “overweight” rating in a research note on Friday, July 17th. Chardan Capital raised their price objective on Emergent Biosolutions from $86.00 to $112.00 and gave the company a “buy” rating in a research note on Friday, July 31st. JPMorgan Chase & Co. initiated coverage on Emergent Biosolutions in a research note on Monday. They set a “neutral” rating on the stock. Zacks Investment Research cut Emergent Biosolutions from a “hold” rating to a “sell” rating and set a $89.00 target price on the stock. in a research note on Wednesday, May 27th. Finally, Wells Fargo & Company raised their target price on Emergent Biosolutions from $85.00 to $93.00 and gave the stock an “overweight” rating in a research note on Thursday, July 2nd. One analyst has rated the stock with a sell rating, three have assigned a hold rating and five have given a buy rating to the company’s stock. Emergent Biosolutions has a consensus rating of “Hold” and a consensus price target of $92.57.

EBS traded down $0.18 on Wednesday, hitting $102.58. The company had a trading volume of 12,568 shares, compared to its average volume of 658,993. The company has a debt-to-equity ratio of 0.63, a current ratio of 2.71 and a quick ratio of 1.91. Emergent Biosolutions Inc has a 52-week low of $46.37 and a 52-week high of $137.61. The stock has a fifty day simple moving average of $115.00 and a 200-day simple moving average of $83.70. The firm has a market capitalization of $5.44 billion, a P/E ratio of 32.01 and a beta of 1.42.

Emergent Biosolutions (NYSE:EBS) last issued its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $1.98 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.53 by $1.45. Emergent Biosolutions had a net margin of 13.52% and a return on equity of 22.92%. The business had revenue of $394.70 million during the quarter. Equities research analysts expect that Emergent Biosolutions Inc will post 6.67 earnings per share for the current fiscal year.

In related news, Director Zsolt Harsanyi sold 6,609 shares of the firm’s stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $133.71, for a total transaction of $883,689.39. Following the completion of the sale, the director now owns 24,579 shares of the company’s stock, valued at $3,286,458.09. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder Fuad El-Hibri sold 40,000 shares of the firm’s stock in a transaction that occurred on Thursday, September 10th. The shares were sold at an average price of $102.73, for a total transaction of $4,109,200.00. Following the sale, the insider now directly owns 1,209,523 shares of the company’s stock, valued at approximately $124,254,297.79. The disclosure for this sale can be found here. Insiders have sold 81,027 shares of company stock valued at $8,898,199 over the last quarter. Company insiders own 14.10% of the company’s stock.

About Emergent Biosolutions

Emergent BioSolutions Inc, a life sciences company, focuses on the provision of specialty products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats (PHTs). Its products address PHTs, including chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travelers' diseases; and opioids.

Featured Story: Circuit Breakers

Want to see what other hedge funds are holding EBS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Emergent Biosolutions Inc (NYSE:EBS).

Institutional Ownership by Quarter for Emergent Biosolutions (NYSE:EBS)

Receive News & Ratings for Emergent Biosolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News